Sanofi (SNY) Competitors

Novartis (NYSE:NVS) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Is NVS or SNY more profitable?

Novartis has a net margin of 25.64% compared to Sanofi's net margin of 21.47%. Novartis' return on equity of 41.08% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	25.64%	41.08%	16.83%
Sanofi	21.47%	16.86%	9.63%

Do analysts rate NVS or SNY?

Novartis currently has a consensus target price of $120.33, suggesting a potential downside of 8.56%. Sanofi has a consensus target price of $62.67, suggesting a potential upside of 26.55%. Given Sanofi's stronger consensus rating and higher possible upside, analysts plainly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	3 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.10
Sanofi	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Is NVS or SNY a better dividend stock?

Novartis pays an annual dividend of $2.60 per share and has a dividend yield of 2.0%. Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.2%. Novartis pays out 37.8% of its earnings in the form of a dividend. Sanofi pays out 38.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Which has more risk & volatility, NVS or SNY?

Novartis has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Does the media favor NVS or SNY?

In the previous week, Novartis had 4 more articles in the media than Sanofi. MarketBeat recorded 23 mentions for Novartis and 19 mentions for Sanofi. Novartis' average media sentiment score of 1.08 beat Sanofi's score of 0.85 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	16 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	12 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings & valuation, NVS or SNY?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$50.32B	5.52	$11.94B	$6.87	19.16
Sanofi	$44.46B	2.74	$6.02B	$4.16	11.90

Do insiders & institutionals believe in NVS or SNY?

13.1% of Novartis shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.